Furthermore, we designed inhibitors based on the crystal structure of the jmjC domain of JMJD6 and selected the most active inhibitor, SKLB325, and conducted a study of the antitumor effects of SKLB325 on ovarian cancer in vivo and in vitro. This evidence concerns the gene JMJD6 and ovarian cancer.